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Abstract: This review provides an updated vision about the recent developments in the field of drug vectorization using 
functional nanoparticles and other nanovectors. From the large number of these nanotechnology-based drug delivery systems 
(DDS) that emerge nearly every week, only a tiny fraction reach a pre-clinical or clinical phase study. In this report, we intend 
to provide contextual information about those nanocarriers and release methods that have shown the best outcomes at in vitro 
and in vivo experiments, highlighting those with proven therapeutic efficiency in humans. From silica-based porous 
nanoparticles to liposomes or polymeric nanoparticles, each one of these nanosystems has its advantages and drawbacks. We 
describe and discuss briefly those approaches that, in our criterion, have provided significant advancements over existing 
therapies at the in vivo level. This work also provides a general view of those commercially available nanovectors and their 
specific area of therapeutic action.  
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1. INTRODUCTION 
 The idea of controlled drug release, as opposed to 
immediate release, refers to the control of the temporal and 
spatial presentation of a therapeutic molecule in the body. 
Sustained-release dosages aim to maintain the drug 
availability within specific therapeutic windows of 
concentration and time. The use of micro- and nanomaterials 
as drug carriers to improve the drug release is a rather old 
concept reported already in the ‘80s when micellar solutions 
were developed for controlled release formulations.[1] Each 
controlled-release system has to be designed not only with 
specific attention on the chemistry of the drug to be 
administrated but also considering the specificities of the 
targeted organ (e.g., crossing physiological barriers, protect 
from quick elimination, etc.).  The advent of nanotechnology 
to the field of medicine made possible novel surface-modified 
nanocarriers for drug targeting and controlled release. This 
review aims to provide an succinct revision of those recently 
developed drug release methodologies that, in our opinion, 
have shown the best performance in animal models or clinical 
applications. We start with a description of some types of 
carriers of use in drug vectorization, followed by few in vitro 
successful experiments with those nanosystems. Finally, we 
appraise the state of the art regarding those commercial 
products of nanocarrier-based drug delivery systems (DDS) 
already approved by the regulatory agencies. 
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2. TYPES OF CARRIERS 
2.1. Liposomes 
Lipidic carriers are suitable for in vivo applications due to 
their similitude with biological structures that veils the 
immune system and result in very long circulation times after 
intravenous administration. The low immune response against 
liposomes is partially due to a reduced phagocytosis, a 
mechanism demonstrated at the in vitro level using blood 
THP-1 monocyte cells in human plasma.[2] Lipid-based 
nanosystems can be divided into non-lamellar and lamellar 
types. The latter are usually obtained from direct assembly of 
amphiphilic building blocks, while the former include 
liposomes, cubosomes and spongosomes.  Liposomes were 
reported about 50 years ago,[3] but it was only two decades 
later that their ability as DDS for therapeutic applications was 
reported.[4] Liposomes can be described as lipid vesicles 
composed of an aqueous core surrounded by lipid bi- or 
multilayers, with average sizes around 50–200 nm. The 
amphipathic character of phospholipids make possible to 
encapsulate either hydrophilic molecules at the aqueous core 
or hydrophobic drugs within the lipid bilayers of the 
liposomes.[5]  
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2.2. Extracellular vesicles  
 An interesting strategy for drug delivery recently 
developed is the use of extracellular vesicles (EVs) of 
different intracellular origin.[6] The highly efficient cell 
uptake mechanisms of EVs allow boosting the delivery doses 
for not only synthetic drugs, but also RNAs or proteins. EVs-
based strategies have the advantage of an easy overcome of 
biological barriers.[7] Additionally, it has been reported that 
curcumin-loaded EVs increase drug’s solubility, stability and 
protection against lipopolysaccharide (LPS)-induced 
microglial activation that causes brain inflammation.[8] The 
different biogenesis of EVs determines the final biological 
function, and can be described with three main classes: 
exosomes, micro-vesicles and apoptotic bodies.[9] In general, 
all types of EVs are composed of a surrounding lipid bilayer, 
and their sizes can be found to vary widely in the literature 
from ≈30 nm to about 2 microns in diameter. Among these, 
exosomes are perhaps the most used because their ability to 
degrade themselves after fusion with lysosomes at the 
intracellular space. It has been reported that exosomal 
encapsulation of doxorubicin and paclitaxel are effective for 
targeting brain tumours.[10] Exosomes are released into the 
extracellular environment through an endo-lysosomal 
pathway, after fusion of multi vesicular endosomes with the 
cell surface (see Figure 1). It has been demonstrated, at both 
in vitro and in vivo levels that exosomes are mediators of 





2.3. Nanoparticles  
The use of functionalized nanoparticles (NPs) as carriers 
for controlled vectorization and release of drugs is based on 
the wide spectrum of physical properties of the NPs core, 
which offers different ways of on-site drug release by 
application of a remote physical stimulus such a light, 
magnetic fields, electromagnetic radiation or ultrasonic 
waves.[12-16] Each one of these strategies has its pros and 
cons, and the choice among them depends on the 
particularities of the specific clinical situation to be 
solved.[17]  
2.3.1. Metallic Nanoparticles  
The developments in synthetic chemistry of the last decades 
have provided many new nanostructured materials with new 
physicochemical properties. These properties can originate 
either from the larger surface/volume ratio of nanometer-sized 
materials, or from subtler size-effects of physical nature (e.g., 
plasmonic resonance, superparamagnetism, etc.). Some 
successful applications reported in biomedicine have been 
connected with the use of semiconductor nanocrystals [18], 
gold nanoparticles and silver nanoshells [19],[20]. Gold 
nanoparticles possess unique photodynamic properties related 
to the absorption of near-infrared radiation, a mechanism 
useful for both diagnosis and therapy. These applications have 
been discussed in detail elsewhere, notably the comprehensive 
works of Dykman et al.[21] and Panchapakesan et al.[22]. 
Several noble metals (Pt, Pd, Ag, Au, etc.) are being explored 
as new, cutting-edge nanostructured biocatalysts due to their 
abundant exposed active sites and highly accessible 
surfaces.[23] Moreover the interaction of metallic Au 
particles with membranes when heated with light has been 
recently studied.[24]. More rare materials like Rhodium 
nanoparticles, synthesized by chemical reduction on 
polymeric micelle templates, have shown better electro 
catalytic oxidation of methanol than the bulk counterparts 
[25], a property that could be adapted to modify cellular bio-
catalytic pathways, provided Rh-toxicity can be kept at low 
values.   
 
2.3.2. Magnetic Nanoparticles 
Magnetic nanoparticles (MNPs) have been projected for 
remotely controlled release since at least since 1969.[26] The 
possibility of remote magnetic actuation on MNPs by dc 
magnetic fields, and their coupling with ac magnetic fields to 
release heat have triggered a plethora of nanodevices in 
biomedicine, many of them with great success.[27],[28] 
Although these applications are well-known and standardized, 
it is remarkable that the physical mechanisms that govern drug 
release under alternate magnetic fields is still a matter of 
controversy, i.e.,  whether a mechanical rather than a thermal 
effect is actually acting locally when radiofrequency (RF) 
magnetic fields are applied. This is partially related to the fact 
that measuring local temperatures (i.e., at the nanometer scale) 
at the particle surroundings has proven extremely 
difficult.[29],[30] In any case, the improvement of the release 
rates when an EMF of a given frequency is applied has been 
clearly demonstrated experimentally.[31] The control of drug 
release with EMF operates in different types of carriers and 
reservoirs; the most used being surface-coated NPs. However, 
other thermoresponsive carriers and reservoirs have been 
reported to be effective, such as thermoresponsive 
ferrogels,[32] thermomagnetic polymer films,[33] and 
polymer films with embedded NPs for synergic uses of drug 
Figure 1. Schematic view of the pathway formation of extracellular 
vesicles, including exosomes, microvesicles, and apoptotic vesicles. 
In many cases, extracellular vesicles have signalling functions 
involved in different biological processes like antigen presentation, 
activation of cell surfaces through major histocompatibility complex 
(MHC) molecules, or transporting miRNAs. 
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release and thermal tissue ablation. Regarding MNPs, the 
selection of magnetic materials of the magnetic cores has been 
based primarily on biocompatibility requirements, making the 
iron-oxide based MNPs the most extensively reported so far. 
A second, more labile criterion for choosing the magnetic core 
relies on those intrinsic magnetic parameters like saturation 
magnetization, magnetic anisotropy, Curie temperature, etc. 
that may improve the magnetic response.  
In a recent work using MNPs in a liposomal formulation,  Guo 
et al.[34] were able to delivery antineoplastic drugs to the 
local tumour environment in animal model. Moreover, they 
used two concurrent physical stimuli (IR light and 
radiofrequency) to trigger the release bursts of the cytotoxic 
drugs within the liposomes, achieving promising therapeutic 
results in vivo.  
Reviews on the different types of metallic and magnetic 
materials used to produce nanoparticles for drug delivery can 
be found elsewhere.[17] Here, we will mention only that for 
the purposes of drug delivery/release nanosystems translated 
into clinics, manufacturing these systems under good 
manufacturing practice (GMP) standards is technically 
achievable. On the other side, as nicely described in Ref.[35], 
the steps to clinical implementation can be difficult and 
lengthy (see also Section 5.2 below) and it is along these 
stages that roughly a 95% of the designed nano-devices fail to 
comply the stringent clinical requirements. A prospective 
analysis of the experimental works of the last years indicated 
that most of the successful applications at the in vivo level are 
based on the use of multi-stimulus DDS like the previously 
described. The emerging picture is that any single activation 
method by itself would be less efficient than the combination 
of two or more of them, as in the successful case of MNPs and 




3. RELEASE MECHANISMS 
 
3.1. Solid Drugs and Solid Matrices 
When a solid dosage form is required for specific therapeutic 
situation, it is essential to warrant that drug dissolution 
(release from the solid matrix) occurs in an appropriate 
manner. Indeed, these drug release kinetic profiles are 
mandatory from regulatory authorities. The quantitative 
analysis of the values obtained in dissolution / release tests are 
usually numerically simulated using models that express the 
dissolution rate as a function of the chemical parameters for 
each dosage form. The models are often empirically derived 
from previous experiments that constitute a databank, 
although in simple cases theoretical models are available.[36] 
Drug release rates from solid dosage forms have been 
described by kinetic models based on the time-dependence of 
the dissolved amount of drug Q(t). These models are usually 
referred as zero-order, first-order, etc, reflecting the functional 
dependence of Q with time. The quantitative interpretation of 
the values obtained in the dissolution assay is facilitated by 
the usage of a generic equation that mathematically translates 
the dissolution curve of each pharmaceutical dosage form. In 
some cases, that equation can be deduced by a theoretical 
analysis of the process, as for example in zero-order kinetics.  
3.2. Solid Drugs in Water-Soluble Polymers 
Many therapeutic drugs have a too-high toxicity profile for a 
direct administration in vivo. For this reason, many molecules 
intended for clinical applications require a modified 
formulation in order to minimize toxicity, as well as to 
improve efficacy of release kinetics. One of the proposed 
ways to achieve these goals has been the use of polymeric 
microspheres and nanospheres that could control the in vivo 
drug release profiles. Solid dispersions in water-soluble 
carriers have been successful in this sense, especially by 
modifying solid-to-liquid release rates of highly hydrophobic 
drugs.[37]  
The concept of a ‘solid dispersion’ covers any dosage of one 
or more active ingredients dispersed  in  a biologically  inert  
solid matrix.[38] [39] The mechanisms behind the observed 
improved release kinetics when compared to solid-solid 
systems are not yet completely understood, but there is some 
consensus regarding the key roles of the crystallographic 
structure and dissolution properties on the final release rates. 
[40] Some models of carrier-controlled kinetics have been 
proposed to calculate the release rates in terms of the 
concentration profile at the polymer layer adjacent to the solid 
surface. [41]  
A reported alternative to control the release kinetics is the use 
of cyclodextrins in polymeric nanospheres and hydrogels.[42] 
Cyclodextrins are cyclic oligosaccharides that have the ability 
to form non-covalent complexes, changing the 
physicochemical properties of the carriers. However, only few 
reports on the actual efficacy have been published,[43] while 
none in vivo tests have been reported to the best of our 
knowledge.  
 
3.3. Coated Tablets  
Perhaps the best-known method used to improve high-density 
formulations is to coat tablets with functional films. 
Specifically, tablet coatings can be used to achieve drug 
stabilization and to modify/delay drug release when oral 
delivery forms are required.[44] A group of successful 
systems developed last decade for colon-specific delivery, 
which reported good specificity in vivo included pressure-
controlled colon delivery capsules (PCDCs) and colonic DDS 
based on pectin and galactomannan coating. The latter DDS 
was reported by Lee et al.[45] and consisted of a tablet coated 
with two specific polysaccharides (pectin and 
galactomannan). The solubility of this coating formulation 
was found to depend on the pH, being insoluble at pH ≥ 7 but 
dissolving fast at those pH ≤ 7 typical of intestinal fluids, 
although the authors did not discuss any model for this pH 
dependence. 
 
3.4 Remote Radiofrequency-Triggered Release 
Non-invasive strategies for remotely triggering drug release 
have been proposed mainly for liposomal-based nanovectors. 
[46] These strategies can be based on different triggering 
stimuli, including (but not restricted to) enzymatic [47], 
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temperature [48], light [49] , magnetic fields [50]  and 
ultrasound. [51] Of special clinical interest is the control of 
drug release profiles on demand by a remote alternating 
magnetic field of low frequency (i.e., at the low part of the RF 
spectrum, 100 – 800 kHz), because of the deep penetration of 
these waves without noticeable interaction with biological 
tissues. In order to load the MNPs with the therapeutic drug to 
be delivered, several coating/functional approaches are 
possible. Iron oxide MNPs attached to porous silica have been 
reported as an efficient way to store chemical payloads and 
release them upon triggering using a RF field.[52] In the same 
work, an increase of desorption rates under applied RF 
magnetic fields has been reported. Remotely triggered DDS 
for cancer applications rely deeply on recent improvements in 
synthesis of MNPs and MNPs-based polymeric materials like 
ferrogels [53] or magnetoliposomes (MLPs) [54]. The 
uniqueness of remote triggering by low-frequency magnetic 
fields relates with is large penetration depth of these waves 
into the human body without interaction with the healthy 
organs or tissues. The price to pay, on the other hand, is the 
need of delivering a ‘heating agent’ i.e., the magnetic 
nanoparticles to the target site to be heated.   
 
3.5 Remote Ultrasound-Triggered Release 
Ultrasound is another of the non-invasive, remote stimulus 
that can be focused on targeted sites for triggering drug 
release. Since ultrasonic waves have the additional effect of 
increasing the permeability of blood–tissue barriers and cell 
membranes, they can be used synergistically to control release 
kinetics.[55] So far, the liposomal formulations are the 
nanocarriers with best responsiveness to ultrasound 
stimulation. Acoustically active liposomes with an average 
size of 800 nm have already been used as contrast agents for 
ultrasound image enhancement[56],[57], while magneto-
liposomes offer the additional possibility of magnetic 
resonance imaging protocols.[58] In the case of acoustic 
imaging, the main mechanism seems to be associated to air 
vesicles encapsulated within liposomes, which determine  
their acoustic activity.[59] Moreover, these liposomes have 
the potential to respond to ultrasound stress by releasing their 
contents.  
 
4. TESTING DRUG DELIVERY/RELEASE IN VITRO  
The main sequence of in vitro events involving targeting, 
internalization and drug release is common to almost any 
DDS, since target sites for most therapies are located at the 
intracellular space. As an example, cationic liposomes possess 
the ability to form complexes (lipoplexes) with nucleic acids 
through electrostatic interaction, which determines their 
transfection efficiency. Improved internalization of DDS is 
usually achieved through surface functionalization with cell 
penetrating peptides or membrane permeable ligands.  
Once at the intracellular space, different DDS are designed to 
react to the cytoplasm conditions to stimulate drug release. In 
such strategies, the nanocarrier is usually designed to be 
sensitivity to cell temperature; pH changes; redox potential 
and/or elevated reactive oxygen species (ROS) levels (see 
Figure 2). The different physical stimuli used to remotely 
activate release mechanisms include radiofrequency (RF), 
near-infrared light (NIR) and ultrasound (US), already 




In vitro release tests are recognized as a significant piece of 
pharmaceutical information since in vitro dosage form can 
influence the release kinetics.[60] Under certain conditions it 
can be a good estimator for assessment of bioequivalence. 
Most of the nanosystems described in the previous section 
have transited different processes towards final clinical or 
biomedical applications. While many of them have been 
tested in vitro for a variety of cell lines, only a relatively small 
number of these proof-of-concept nanovectors have been 
tested in animal models (see below). In the following 
subsections we review the most representative approaches 
tested so far in primary cell types, and some that have gone all 
the way through the in vitro tests to the clinical approval. 
Polymer-based carriers are among the systems extensively 
tested in vitro.[61] The presence of primary, secondary, and/or 
tertiary amine groups provide effective, linkable surfaces with 
negatively charged molecules of biological interest (e.g., 
nucleic acids). Several cationic polymers have been tested, 
and Olden et al.[62] reported that a subset of sunflower-
shaped polymer NPs could mediate gene transfection on both 
cultured and primary cells with efficiencies up to 50% in the 
Jurkat human T cell line. Additionally, these NPs were 
reported to show minimal concomitant toxicity (> 90% 
viability), opening possible ways to optimize primary T-cell 
transfection conditions including activation time, cell density, 
DNA dose, culture media, and cytokine treatment.  
 
Another approach that has consensus regarding its efficacy in 
vitro is the use of ferritin-based nanocarriers. Ferritin is an 
iron-storage protein consisting of 24 subunits that self-
assemble to form spherical nanocages of around 12 nm in 
Figure 2 Schematic illustration of drug carrier internalization into the 
intracellular space and its activation by different external or internal stimuli.    
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diameter with an interior cavity of 8 nm.[63] Chemical groups 
(N- and C- terminal sites) present at the outer surface provide 
the possibility to bind different compounds. Zhang and co-
workers presented the use of apoferritin as delivery agent, 
with reports of low cytotoxicity and low immune 
response.[64] Translocation of apoferritin cage allowed the 
encapsulation of doxorubicin (Dox) inside the cavity forming 
a stable complex (H-Dox). Due to the chemical and size 
properties, H-Dox is able to pass the blood–brain barrier in 
vivo. Zhang et al. showed its potential using cerebellar 
organotypic cultures and suggested the possibility of using a 
double chambered cage containing different targets. This idea 
was further developed by Kin et al.[65] who described the 
formation of double-chambered ferritin cage NPs in which the 
first N-terminal chamber is loaded with peptide and the 
second C-terminal chamber to be loaded with a tumour-
targeting pro-apoptotic peptide and the fluorescent protein 
GFP, respectively.  
 
Related to the above approach, micellar nanocarriers have 
been also used at the in vitro level to test their multifunctional 
potential. For example, Jing et al. [66] presented a micellar 
nano-platform capable of simultaneously showing high cell 
penetration and nuclear targeting through pH-triggered 
surface charge reversal. The results reported on mice bearing 
4T1 breast tumour showed enhanced cellular internalization 
and low side effects of encapsulated drugs, while keeping 
therapeutic efficacy. It is interesting to note that within the 
tumour tissue (acidic pH) the system exhibited negative to 
positive charge reversal, facilitating the cell internalization 
and subsequent nuclear targeting. The anticancer drug model 
used, 10-hydroxycamptothecin, was conjugated to methoxy 
polyethylene glycol to improve the cytotoxicity.  
Liposomes are perhaps the most successful formulation for 
clinical drug delivery.  Since they will be discussed in detail 
in the next Section regarding their in vivo application, here we 
will only mention that surface-modified liposomes having 
arginine-rich cell penetrating peptides and transferrin [67] 
were reported to improve targeting onto A2780 ovarian 
carcinoma cells via the over-expressed transferrin receptors. 
In the same way Patil et al. [68] reported liposomes containing 
a dual chemotherapeutic load of lipophilic mitomycin C and 
doxorubicin.  
A lipid-polymer hybrid liposomal nano-platform based on 
hyaluronic acid-magnetic nanoparticle-liposomes have shown 
also good results as a vehicle for docetaxel by improving the 
cellular uptake in human breast cancer cells.[69] In addition, 
they proved the double effect of chemotherapy and 
thermotherapy under near-infrared laser irradiation (NIR, 808 
nm).[70]  
 
As mentioned in Section 1, inorganic metallic NPs have also 
been exploited to transport and release therapeutic drugs by 
chemical or physical stimuli. The most extensively 
investigated material is Au-NPs. Functionalized gold 
nanoparticles are known to have good biocompatibility and 
versatile shape and size, providing a tunable response to 
physical stimuli. Recently, Hernández Montoro et al. [71] 
tested a drug release system based on Au-nanostars  coated 
with a mesoporous silica in HeLa cells. The silica shell was 
loaded with doxorubicin (Dox) and coated with octadecyl-
trimethoxy-silane and paraffin to retard the release of Dox. 
Low cytotoxicity confirmed the efficacy of the coating to 
prevent Dox leaking, and using a 808 nm laser irradiation the 
release profile was accelerated. Spherical Au-NPs have been 
also tested in vitro, using different coatings, with different 
degrees of success.[72]  
 
The development of drug-vehicles made of materials with 
dual effect has also witnessed some successful in vitro 
experimentation. Rodrigues et al. [73] used graphene-based 
magnetic nanoparticles functionalized with pluronic F-127, 
demonstrating efficacy on concurrent hyperthermia and pH 
stimuli-responsive drug delivery on Hep-G2 cells. This 
nanosystem showed the potential ability to transport 
therapeutic doses of doxorubicin, and to respond to both pH 
changes in tumour environment and to external magnetic 
fields. In addition, albumin-based MNPs with low toxicity and 
immunogenicity, have been tested in vitro by Nostari et al. 
[74], who applied albumin-coated MNPs attached with 
curcumin (CUR) in vitro, aiming to decrease tumour growth 
through proliferation suppression. Although this compound 
presents really promising properties, it is not commonly used 
due to the short biological half-life and low solubility, which 
results in poor absorption and thus low bioavailability through 
the oral route.  
 
5. TARGETED NANOCARRIERS FOR IN VIVO DRUG 
DELIVERY  
 
Current nano-based drug delivery systems (DDS) are still far 
from the concept of “magic bullet” created by Paul Ehrlich in 
early 1900’s. Most of them rely on passive drug accumulation 
in desired tissues, taking advantage of  physiological 
conditions like the EPR effect, which has been described since 
approximately 30 years.[75] However, only a marginal 
increase in drug concentration has been reached with 
passively guided strategies, and this often represents only a 
very small fraction of the total dose administered. For this 
reason, active targeting is necessary to achieve specific 
tissue/organ accumulation. Active drug transport is based on 
molecular recognition processes to deliver drugs to specific 
pathological sites. Most active guided nanosystems employ 
targeting ligands at their surface, including organic molecules, 
antibodies, aptamers, proteins or peptides.[76] 
Drug delivery to the central nervous system (CNS) is often 
limited by the very low permeability of the blood-brain barrier 
(BBB), which is composed of a continuous and charge-
polarized endothelial cell layer. Therefore, most of the drugs 
must travel across a trans-cellular hurdle employing a set of 
transporters before targeting brain tissues. There are already 
good recent reviews on the use of diverse nanocarriers for 
treating neurodegenerative and other CNS diseases [77, 78] 
and thus here we mention only some examples. For instance, 
a PEGylated liposomal system functionalized with transferrin 
(Tf) and penetratin (Pen) for targeting BBB endothelial cells 
was recently tested for transfection both in vitro and in 
vivo.[79] In the latter, this PenTf-liposome was used to assess 
gene delivery of β-galactosidase-peptide through monitoring 
β-galactosidase expression in mice tissues. The results 
evidenced that PenTf-liposomes were able to cross BBB and 
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accumulate in brain (12% of the injected dose), and had better 
transfection capacity than plain liposomes.   
Recently, Shahin et al. [80] synthesized a nanocarrier based 
on PEI-coated mesoporous silica nanoparticles (MSNs) 
conjugated with hyaluronic acid (HA) for targeting CD44 
expressing-recurrent ovarian cancer stem cells. A novel small 
interfering RNA against TWIST protein (siTWIST) was further 
conjugated with the MSNs-HA particles aiming to suppress 
TWIST and reducing chemoresistance when administered in 
combination with cisplatin. In vivo results showed 60% 
tumour growth suppression in the cisplatin group compared to 
control, MSN-siTWIST reduced it an additional 20%, but the 
MSN-HA-siTWIST + cisplatin group exhibited the best 
efficacy, reducing almost a 90% the tumor volume. Future 
work could show the potential applications of this system in 
drug delivery. 
Another option for active drug delivery of antineoplastic 
drugs is targeting the tumour vasculature. RGD peptide can 
bind to αvβ5 integrin, which is often overexpressed in some 
types of tumours. Song et al. [81] developed a novel 
nanostructured lipid carrier composed of a mixture of solid 
and liquid state lipids conjugated with RGD and encapsulating 
anticancer drug temozolomide (TMZ) for glioblastoma 
multiforme treatment. RGD-TMZ/NLCs efficacy were tested 
on U87 MG-bearing mice, treatments were given 
intravenously and repeated once every three days over a 
period of 21 days. At the end of the study, RGD-TMZ/NLCs 
showed a 4-fold inhibition of tumour growth compared with 
the free drug treatment group. Furthermore, tumour growth 
inhibition was significantly increased compared with non-
RGD guided NLCs, confirming active targeting to tumour 
vasculature via RGD peptide. 
 
5.1. Stimuli-responsive control of drug release 
 
Controlling drug release rates using external stimuli on 
nanocarriers at target sites is a persistent challenge. This 
noninvasive strategy has still many issues that need to be 
solved before it can be safely translated into clinics. The 
research of new components for nanocarriers has allowed the 
development of systems with dual or multi stimuli-triggered 
drug release mechanisms through both internal (pH, 
temperature, redox potential, ROS generation, enzymes, 
hypoxia) and external (ultrasound, light, radiofrequencies, 
magnetic fields) stimulus. There are many tests currently 
running on these novel carriers, both in vitro and in vivo. 
[82],[83],[84] 
The liposomal formulations are perhaps the more successful 
DDS currently employed in clinics, due to their 
physicochemical compatibility, pharmacokinetic behaviour 
and delivery efficacy. Thus, liposomes have been used as the 
starting point to build many stimuli-responsive DDS. For 
example, pegylated liposomes loaded with cisplatin and 
MNPs (i.e., magnetoliposomes) have been tested in vitro and  
in vivo regarding their transition temperature (Tm), 
encapsulation efficiency and drug release profiles.[85]. This 
new type of DDS showed the capacity of inhibiting tumour 
growth, and when combined with magnetic hyperthermia 
treatments a complete obliteration of the tumours was 
reported.[85]   
Another promising formulation of magneto-liposomes 
encapsulating both iron oxide magnetic nanoparticles and a 
commercially available photosensitizer (Foscan, m-THPC) 
was tested for a combination of magnetic hyperthermia 
(MHT) and photodynamic therapy (PDT) for tumour ablation. 
The formulation yielded satisfactory ratios of both agents and 
showed good stability in vitro (less than 20% of m-THPC 
released during the first seven days). In vivo, combination of 
MHT and PDT with the m-THPC-loaded MLPs showed better 
efficacy than individual treatments and was able to completely 
eradicate tumours in A431 xenografts.[86] 
After the first applications of hyperthermia, surviving cancer 
cells often develop thermo-resistance associated with 
increased expression of heat shock proteins (HSPs) reducing 
subsequent heating efficacy and tumour relapses. 17-AGG, an 
HSP90 inhibitor derived from geldanamycin, has shown 
capacity for killing tumour cells by inhibiting HSP90, 
however, its poor solubility in water limits its use.  In order to 
overcome this limitation, Yang et al. [87] encapsulated 17-
AGG inside thermosensitive MLPs and further modified them 
for targeting CD90+ liver cancer stem cells (CD90@17-
AGG/TMs). To prove the antitumor efficacy of the 
formulation, CD90@17-AGG/TMs were intratumorally 
injected in CD90+LCSCs-bearing mice and 24h after 
administration, tumours were exposed to an alternating 
current magnetic field (ACMF, f=200 kHz, I=20 A) for 1 h, 
every other day for a week. Compared to the other 
experimental groups, CD90@17-AGG/TMs + ACFM showed 
superior reduction of tumour size (83.44 ± 5.78 % inhibition 
rate) and increased number of apoptotic cells in tumour tissue. 
Dual stimuli-responsive polymeric micelles composed of 
methoxy poly(ethylene glycol)-co-poly (lysine) (mPEG-
PLys) and a mixture of fatty acids including linoleic acid, α-
linoleic acid and araquidonic acid as building blocks were 
developed by Gao et al. Chlorin e6 (Ce6) was loaded within 
the micelle core. Ce6 is a photosensitizer, which, upon laser 
irradiation, can produce highly reactive oxygen species 
(ROS). These ROS not only exerts a cytotoxic effect on cancer 
cells but also act like a trigger mechanism, causing lipid 
peroxidation of the unsaturated fatty acids and destabilizing 
the vehicle for a rapid release of Ce6 and a maximization of 
the ROS effects.  This hypothesis was tested in vivo in tumour-
bearing mice after intravenous administration of either free 
Ce6 or its micellar form (RMAA). The authors found that after 
24h post administration, Ce6 concentration in tumour tissue 
was much higher in RMAA group; also RMAA exhibited the 
best antitumor outcome reducing tumour volume and 
improving survival time[88]. 
Shi et al. demonstrated another example of ROS-mediated 
drug release.[89] These authors succeeded in formulating 
mesoporous TiO2 nanoparticles with entrapped doxorubicin 
and coupling dsDNA fragments at the surface to block 
doxorubicin leakage. The nanosystem exhibited very good 
stability under physiological conditions. However, under 
ultrasound stimulation TiO2 can produce ROS that causes 
dsDNA shearing and therefore increasing doxorubicin 
release. This was first demonstrated in vitro, where 
nanoparticles without ultrasound stimulation released only 
11% of encapsulated doxorubicin after 48 h while 83% was 
released when ultrasound was applied. These results 
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encouraged authors to analyse the possible antitumor efficacy 
in vivo. NBMTNs were intravenously injected in MCF-
7/ADR tumour bearing mice and ultrasound irradiation 
(1W/cm2, 120S) was performed for 24h on tumour site. 
Results showed that NBMTNs + US causes a 5-fold higher 
inhibition of tumour growth compared with control group and 
4-fold inhibition compared with free doxorubicin or 
NBMTNs without ultrasound. 
A novel system composed by redox/enzyme self-assembling 
polymeric NPs has shown promising results.[90] This 
complex system was obtained by conjugating chondroitin 
sulfate (CS) with deoxicholic acid (DOCA) through a redox-
sensitive disulfide bond. A therapeutic drug, docetaxel 
(DTX), was further encapsulated within these nanoparticles. 
Hyal-1 is a lysosomal enzyme overexpressed in various types 
of cancer cells, associated with growth, metastasis and 
angiogenesis of tumours. Since HA can be degraded by Hyal-
1 and the structural similarities between CS and HA, it is 
believed that Hyal-1 can also degrade CS. Therefore, 
controlled release in these nanoparticles can be achieved by 
Hyal-1 induced CS degradation and glutation (GSH) induced 
cleavage of disulphide bonds. This hypothesis was tested both 
in vitro in B16F10 cells (murine melanoma) and in vivo using 
B16F10 tumour bearing mice. Compared with commercial 
docetaxel (Taxotere®), CSCD showed a 4-fold higher area 
under the receiver-operating curve in tumor. Furthermore, 
CSCD showed increased tumor growth inhibition and reduced 
lung metastasis.  
Theranostic nanosystems appear to be the next step towards 
personalized medicine. Formulations that can be applied for 
both diagnostic and therapeutic purpose have attracted much 
attention in the last years. As an example, the recently 
reported nanosystem made of liposomes with co-encapsulated 
perfluorocarbon (PFC), hollow gold nanospheres (HAuNS),  
and doxorubicin (DOX), was intended for ultrasound 
imaging, photothermal therapy (PTT) and temperature-
controlled drug release purposes, all triggered by NIR light 
irradiation. This and other types of new, multipurpose 
nanosystems have started to provide quite promising results 
both in vitro and in vivo.[91]  
 
5.2. Translation into clinics 
 
Nanotechnology came into the field of drug delivery systems 
(DDS) about two decades ago, opening new ways to improve 
the spatial and temporal control of the therapeutic release 
profiles. This resulted in a large number of new concepts and 
nanodevices with proven experimental success in vitro or in 
vivo. But only a much smaller fraction of all these new DDS 
developed was able to obtain approval to be used in human 
clinics.  
Figure 3 resumes the main key-points involved from the initial 
development of any DDS to the final clinical approval and 
commercialization. In spite of the fact that many new 
developments subjected to clinical trials use clinically 
approved drugs, a full characterization phase for each DDS is 
required since small changes in composition or 
physicochemical parameters like particle size, zeta potential 
or drug-release patterns could cause a completely different 
behaviour. After the formulation phase, preclinical studies 
both in vitro and in vivo are necessary to prove the 
bioavailability, efficacy and safety properties of the 
nanocarrier before their use in patients. Furthermore, clinical 
studies from phase I to phase III must guarantee the 
bioequivalence, safety profile and better/similar efficacy 
compared with the standard drug before finally being 
approved in clinics. 
 
 
Figure 3 Key-points along the efficacy/safety studies for new nanomaterial-
based drug delivery systems, before they can be approved for clinical uses. 
 
In the last few years, a great number of experimental 
nanocarriers have been developed and tested in preclinical 
stages.[92] Unfortunately, despite the substantial research 
showing promising results both in vitro and in vivo with this 
nanomaterials for controlled drug delivery and release, there 
are only few of them that have been successfully translated to 
clinical studies and even less have been approved for clinical 
use (see Table 1). However, owing to the increasing 
information in molecular biology of different diseases and the 
positive results in preclinical stages, the number of 
nanomaterials in clinical stages is expected to increase in the 
next years.[93],[94],[95] 
CONCLUSION 
Many long-standing glitches that hindered therapeutic 
applications of drug delivery systems (DDS) have been 
overcome by the incorporation of nanotechnology and 
nanomaterials into the main original conception. Although 
solid matrix formulations are still irreplaceable for some 
therapeutic goals, nanosystems with active control of release 
kinetics are now a real possibility. The review of the current 
literature shows that those DDS currently available have 
improved the pharmacological outcomes of several 
therapeutic strategies, making a real impact on the clinical 
activity. Among the DDS formulations with evident success, 
anticancer-drug delivery systems stand out. Moreover, the 
basic templates already developed for some clinically-
approved DDS can be adapted for new drugs still to be 
synthesized from the (also) fast-growing field of chemical 
engineering and drug screening. On the other hand, the 
success regarding DDS having remote wireless control of 
drug release is yet to be proven at clinical stages. These would 
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be the next generation DDS that could resemble the long-
standing conception of a ‘magic bullet’.     
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Table 1. Nanotechnology-based drug delivery systems approved for clinical use  
 
Category Name Drug Disease 
Nanocrystals ZYPAdhera Olanzapine 




KadcylaTM Trastuzumab / emtansine Metastatic breast cancer 
Adcetris® Brentuximab vedotin 
Hodgkin’s Lymphoma, anaplastic large cell 
lymphoma 
Mylotarg® Gentuzumab / Ozogamicin Acute myeloid leukemia 





Kaposi’s Sarcoma, ovarian and breast cancer, 
Multiple myeloma 
Myocet® Doxorubicin 
Combination therapy for metastatic breast 
cancer 
LipoDox ® Doxorubicin Kaposi’ sarcoma, breast and ovarian cancer 
Daunoxome ® Daunorubicin Kaposi’s sarcoma 
DepoCyt TM Cytarabine Lymphomatous meningitis 
Marqibo ® Vincristine Acute lymphoblastic leukemia 
Onco TCS® Vinciristine Relapsed aggressive non-Hodgkin’s lymphoma 
Onivyde® Irinotecan Pancreatic cancer 
Mepact Mifamurtide Osteosarcoma 
Abelcet® Amphotericin B Severe fungal infections 
Ambisome® Amphotericin B Fungal infections 
Amphotec® Amphotericin B Aspergillosis, visceral leishmaniasis 
DoceAqualipTM Docetaxel 
Breas, gastric, head and neck and prostate 
cancers 
DepoDur® Morphine Postoperative pain 
Epaxal® Hepatitis A vaccine Hepatitis A 
Inflexal® V Influenza virus vaccine Influenza virus infections 
Visudyne® Verteporfin 






Neocarzinostatin Liver cancer 
Lupron Depot® Leuprolide 
Prostate, breast, ovarian and endometrial 
cancers.  Endometriosis, infertility, benign 
prostatic hyperplasia 
Abraxane® Paclitaxel 
Metastatic breast cancer, NSCLC, pancreatic, 





Metastatic or recurrent breast cancer, 





Acute lymphoblastic leukemia, Non-Hodgkin’s 
lymphoma 
Adagen® Adenosine deaminase Severe combined immunodeficiency (SCID) 
Pegasys® IFN-α-2a Hepatitis B and C 
CImzia® Fab’ fragment against TNFα 
Active rheumatoid arthritis, axial 
spondyloarthritis, ankylosing spondylitis, no-




NanoTherm® Iron Oxide Nanoparticles Glioblastoma 
 
 
